Clots: Browse the Evidence

This webpage is no longer being updated and will soon be removed from the CADTH website. In the future, to access CADTH resources on this topic, visit cadth.ca/reports and type “anticoagulants” in the search bar.

• Anticoagulant Antidotes
• Atrial Fibrillation
• Venous Thromboembolic Events
• Point-of-Care INR Testing for Patients on Oral Anticoagulant Therapy
• Miscellaneous

Anticoagulant Antidotes

• Antidote Treatments for the Reversal of Direct Oral Anticoagulants (Issues in Emerging Health Technologies, June 2015)

Atrial Fibrillation

• CHAD65 and CHA2DS2-VASc Risk Stratification Tools for Patients with Atrial Fibrillation: A Review of Clinical Effectiveness and Guidelines (Summary With Critical Appraisal, May 2017)
• Dabigatran for Stroke Prevention in Atrial Fibrillation: A Review of the Evidence on Safety (Summary With Critical Appraisal, April 2017)
• Edoxaban (Lixiana NVAF) (CADTH Common Drug Review Recommendation, March 2017)
• Rivaroxaban (Xarelto) (CADTH Common Drug Review Recommendation, July 2013)
• Dabigatran etexilate (Pradaxa) (CADTH Common Drug Review Recommendation, July 2013)
• Apixaban (Eliquis) (CADTH Common Drug Review Recommendation, March 2013)
• Monitoring for Atrial Fibrillation After Stroke or Transient Ischemic Attack (Optimal Use Project, September 2015)
• Antithrombotic Therapy for Patients With Atrial Fibrillation (Therapeutic Review, June 2012)
• New Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation (Therapeutic Review, January 2012)
• Optimal Warfarin Management for Prevention of Thromboembolic Events in Patients With Atrial Fibrillation (Optimal Use Project, August 2011)
• Dabigatran for Stroke Prevention in Atrial Fibrillation: A Review of the Evidence on Safety (Summary With Critical Appraisal, March 2012)
• Apixaban and Rivaroxaban for Stroke Prevention in Atrial Fibrillation: Safety (Reference List, March 2014)

All reports apply only to patients with non-valvular atrial fibrillation.

Venous Thromboembolic Events

Venous thromboembolism, or a venous thromboembolic event (VTE), may include deep vein thrombosis (DVT) or pulmonary embolism (PE).

Prevention of VTE After Orthopedic Surgery

• Portable Compression to Prevent Venous Thromboembolism After Hip and Knee Surgery: The ActiveCare System (Issues in Emerging Health Technology, March 2016)
• Apixaban (Eliquis)  (CADTH Common Drug Review Recommendation, June 2012)
• Dabigatran etexilate (Pradaxa)  (CADTH Common Drug Review Recommendation, January 2009)
• Rivaroxaban (Xarelto)  (CADTH Common Drug Review Recommendation, December 2008)
• Dabigatran or Rivaroxaban Versus Other Anticoagulants for Thromboprophylaxis After Major Orthopedic Surgery: Systematic Review of Comparative Clinical Effectiveness and Safety (Health Technology Assessment, May 2009)
• Anticoagulant Use Pre- and Post-Hip Fracture and Other Emergency Orthopedic Surgery: A Review of Guidelines (Summary With Critical Appraisal, March 2015)
• Low-Molecular-Weight Heparins Versus New Oral Anticoagulants for Long-Term Thrombosis Prophylaxis and Long-Term Treatment of DVT and PE: A Review of the Clinical and Cost-Effectiveness (Summary With Critical Appraisal, May 2013)
• Rivaroxaban for Hip Replacement Surgery: 14-Day Versus 35-Day Duration (Reference List, March 2010)

Treatment of VTE, and Secondary Prevention

• Anticoagulants for VTE Prevention in the Hospital Setting  (Technology Review, April 2017)
• Edoxaban (Lixiana VTE) (CADTH Common Drug Review Recommendation, March 2017)
• Low-Molecular-Weight Heparin (Ontario Drug Policy Research Network drug class review, May 2016)
• Direct Oral Anticoagulants for the Treatment of Venous Thromboembolic Events: Economic Evaluation (March 2016)
• Direct Oral Anticoagulants for the Treatment of Venous Thromboembolic Events: A Systematic Review and Network Meta-Analysis (Drug Safety and Effectiveness Network, January 2016)
• Post-Operative Anticoagulation of Elderly Surgical Patients with Impaired Renal Function: Clinical Effectiveness and Guidelines (Reference List [no evidence found], November 2015)
• Apixaban (Eliquis) (CADTH Common Drug Review Recommendation, May 2015)
• Rivaroxaban (Xarelto) (CADTH Common Drug Review Recommendation, March 2014)
• Low-Molecular-Weight Heparins Versus New Oral Anticoagulants for Long-Term Thrombosis Prophylaxis and Long-Term Treatment of DVT and PE: A Review of the Clinical and Cost-Effectiveness (Summary With Critical Appraisal, May 2013)
• Low-Molecular-Weight Heparins Versus Warfarin for the Long-Term Prevention or Treatment of Deep Vein Thrombosis or Pulmonary Embolism: A Review of the Clinical and Cost-Effectiveness (Summary With Critical Appraisal, May 2013)
• Risk Factors to Consider for Extended Anticoagulant Therapy: A Review of Guidelines (Summary With Critical Appraisal, February 2013)
• Rivaroxaban for the Treatment of Deep Vein Thrombosis: A Review of Guidelines (Summary With Critical Appraisal, December 2012)

Point-of-Care INR Testing for Patients on Oral Anticoagulant Therapy

• Point-of-Care Testing of the International Normalized Ratio (INR) for Patients Taking Warfarin or Other Vitamin K Antagonists (Optimal Use Project, April 2013)

Miscellaneous

• Heparin (5,000 u/0.5 mL) for Catheter Lock or Flush: An Update Regarding the Clinical Effectiveness, Safety, and Guidelines  (Reference List, Sept. 2017)
• Heparin for Maintaining Patency of Peripherally Inserted Central Catheters in Neonates: Evidence-Based Guidelines (Summary of Abstracts [no evidence found], November 2015)
• Endovascular Therapy for Patients With Ischemic Stroke: A Review of the Clinical and Cost-Effectiveness and Guidelines (Summary With Critical Appraisal, October 2015)
• Fondaparinux Versus Enoxaparin for Acute Coronary Syndromes: Comparative Clinical Effectiveness and Cost-Effectiveness (Summary With Critical Appraisal, September 2015)
• Measurement of Direct Anti-Xa Activity of Rivaroxaban (INESSS, April 2014)